We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Drug accelerator Cydan unveiled its third orphan drug company: Tiburio Therapeutics, which starts life with $31 million in series A funding and a pair of clinical-stage compounds licensed from Ipsen.....